Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05791851 · ClinicalTrials.gov registry record
Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders
A clinical trial, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- 31
- Enrollment target
NCT05791851 is a clinical trial that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 31 participants.
The verdict
NCT05791851 has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- 31 participants
- Enrollment target
Study Summary
The goal of this natural history study is to examine the immune responses to the Heplisav-B vaccine in Veterans living with HIV who were non-responders to prior HBV vaccination. A comparison group of HBV vaccine nonresponders without HIV infection will be enrolled to characterize the HIV-associated immune alterations that affect vaccine response. The investigators hypothesize that TLR9-mediated innate immune stimulation with Heplisav will elicit HBV seroprotection despite prior vaccination failures in persons living with HIV, compared to HIV uninfected individuals. Participants eligible for Heplisav-B vaccination will be asked to provide blood samples at multiple timepoints before and after their vaccination.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-10-23 |
| Est. Completion | 2022-06-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05791851
The ClinicalTrials.gov registry entry for NCT05791851 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05791851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05791851 about?
NCT05791851 is a clinical study titled "Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders". The goal of this natural history study is to examine the immune responses to the Heplisav-B vaccine in Veterans living with HIV who were non-responders to prior HBV vaccination. A comparison group of HBV vaccine nonresponders without HIV infection will be enrolled to characterize the HIV-associated ...
What is the current status of trial NCT05791851?
This trial is currently completed. The enrollment target is 31 participants. The study started on 2019-10-23. Estimated completion is 2022-06-14.
Who is sponsoring clinical trial NCT05791851?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.